Skip to main content
. 2020 Dec 7;11:604318. doi: 10.3389/fimmu.2020.604318

Figure 4.

Figure 4

Recombinant antibody production (%) with IgE, Vκ1 and mutated Vκ1 SPs, (Vκ1 P18R and Vκ1 P18S) against the wild-type Vκ1|VH3 Pertuzumab (blue) and Trastuzumab (orange) models.